Press release
Alzheimer's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Scie
The Alzheimer's Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Alzheimer's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alzheimer's Disease Market.
Some of the key takeaways from the Alzheimer's Disease Pipeline Report:
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Alzheimer's Disease treatment therapies with a considerable amount of success over the years.
• Alzheimer's Disease companies working in the treatment market are Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others, are developing therapies for the Alzheimer's Disease treatment
• Emerging Alzheimer's Disease therapies in the different phases of clinical trials are- NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others are expected to have a significant impact on the Alzheimer's Disease market in the coming years.
• In March 2024, MapLight Therapeutics, a clinical-stage biopharmaceutical company focused on developing targeted novel treatments for debilitating CNS disorders, announced the start of a Phase 1 clinical trial for ML-007/PAC. This is an extended-release fixed-dose combination of the novel investigational muscarinic agonist ML-007 and a precision-matched peripherally active anticholinergic (PAC). The trial builds on findings from three previous Phase 1 trials that assessed the safety and tolerability of ML-007 with PAC. The data from this new trial will guide the dosing regimen for upcoming Phase 2 trials targeting schizophrenia and Alzheimer's disease psychosis. The company plans to start its first Phase 2 trial of ML-007/PAC in schizophrenia later this year.
• In January 2024, AmyriAD Therapeutics plans to assess its leading Alzheimer's disease small molecule candidate, AD-101, in three forthcoming Phase III studies.
• In July 2023, Following a conclusion that a confirmatory trial demonstrated clinical benefit, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), intended to treat adult patients with Alzheimer's Disease, to conventional approval. Leqembi is the first amyloid beta-directed antibody for the treatment of Alzheimer's disease to transition from an accelerated approval to a conventional approval.
Alzheimer's Disease Overview
Alzheimer's disease is a progressive neurodegenerative disorder that primarily affects older adults, leading to cognitive decline, memory loss, and changes in behavior and personality. It is the most common cause of dementia, accounting for 60-80% of dementia cases.
Get a Free Sample PDF Report to know more about Alzheimer's Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Alzheimer's Disease Drugs Under Different Phases of Clinical Development Include:
• NRDN-201: Neurodon
• ST-501: Sangamo Therapeutics
• SNK 01: NKGen Biotech
• ASN51: Asceneuron
• TB 006: TrueBinding
• AL002: Alector
• CT-1812: Cognition Therapeutics
• Blarcamesine: Anavex Life Sciences
• E 2814: Eisai Co Ltd
• Simufilam: Cassava Sciences, Inc.
• KarXT: Karuna Therapeutics
• NE3107: BioVie
Alzheimer's Disease Route of Administration
Alzheimer's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Alzheimer's Disease Molecule Type
Alzheimer's Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Alzheimer's Disease Pipeline Therapeutics Assessment
• Alzheimer's Disease Assessment by Product Type
• Alzheimer's Disease By Stage and Product Type
• Alzheimer's Disease Assessment by Route of Administration
• Alzheimer's Disease By Stage and Route of Administration
• Alzheimer's Disease Assessment by Molecule Type
• Alzheimer's Disease by Stage and Molecule Type
DelveInsight's Alzheimer's Disease Report covers around 120+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Alzheimer's Disease product details are provided in the report. Download the Alzheimer's Disease pipeline report to learn more about the emerging Alzheimer's Disease therapies
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Alzheimer's Disease Therapeutics Market include:
Key companies developing therapies for Alzheimer's Disease are - AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd., Janssen Pharmaceuticals, Inc., Johnson & Johnson, Novartis AG, Zydus Lifesciences Ltd (CADILA), Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, Amneal Pharmaceuticals Inc., Macleods Pharmaceuticals Ltd., Viatris Inc., Lupin Ltd, Cipla Ltd., Torrent Pharmaceuticals Ltd., Unichem laboratories ltd, Lannett Inc., and others.
Alzheimer's Disease Pipeline Analysis:
The Alzheimer's Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Alzheimer's Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer's Disease Treatment.
• Alzheimer's Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Alzheimer's Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alzheimer's Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alzheimer's Disease drugs and therapies
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Alzheimer's Disease Pipeline Market Drivers
• Increase in prevalence of Alzheimer's Disease (AD), rising geriatric population are some of the important factors that are fueling the Alzheimer's Disease Market.
Alzheimer's Disease Pipeline Market Barriers
• However, clinical trials are more complicated, costly, and slower than trials for other diseases., lack of clear diagnosis and other factors are creating obstacles in the Alzheimer's Disease Market growth.
Scope of Alzheimer's Disease Pipeline Drug Insight
• Coverage: Global
• Key Alzheimer's Disease Companies: Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Sciences, Eisai Co Ltd, Cassava Sciences, Inc., Karuna Therapeutics, BioVie, and others
• Key Alzheimer's Disease Therapies: NRDN-201, ST-501, SNK 01, ASN51, TB 006, AL002, CT-1812, Blarcamesine, E 2814, Simufilam, KarXT, NE3107, and others
• Alzheimer's Disease Therapeutic Assessment: Alzheimer's Disease current marketed and Alzheimer's Disease emerging therapies
• Alzheimer's Disease Market Dynamics: Alzheimer's Disease market drivers and Alzheimer's Disease market barriers
Request for Sample PDF Report for Alzheimer's Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/alzheimers-disease-ad-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Alzheimer's Disease Report Introduction
2. Alzheimer's Disease Executive Summary
3. Alzheimer's Disease Overview
4. Alzheimer's Disease- Analytical Perspective In-depth Commercial Assessment
5. Alzheimer's Disease Pipeline Therapeutics
6. Alzheimer's Disease Late Stage Products (Phase II/III)
7. Alzheimer's Disease Mid Stage Products (Phase II)
8. Alzheimer's Disease Early Stage Products (Phase I)
9. Alzheimer's Disease Preclinical Stage Products
10. Alzheimer's Disease Therapeutics Assessment
11. Alzheimer's Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Alzheimer's Disease Key Companies
14. Alzheimer's Disease Key Products
15. Alzheimer's Disease Unmet Needs
16 . Alzheimer's Disease Market Drivers and Barriers
17. Alzheimer's Disease Future Perspectives and Conclusion
18. Alzheimer's Disease Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Alzheimer's Disease Epidemiology https://www.delveinsight.com/report-store/alzheimers-disease-ad-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Alzheimer's Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Orthopedic Trauma Devices Market https://www.delveinsight.com/report-store/orthopedic-trauma-devices-market
Global Orthopedic Trauma Devices Market was valued at USD 7.01 billion in 2023, growing at a CAGR of 6.43% during the forecast period from 2024 to 2030 to reach USD 10.15 billion by 2030. The demand for orthopedic trauma devices is witnessing growth due to the rising number of accident and trauma cases, growing prevalence of degenerative bone disorders, the rising number of sports-related injuries, rising demand for technologically advanced products, and increasing geriatric population are expected to drive product demand in the global orthopedic trauma devices market.
Acute Ischemic Stroke Market
https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
DelveInsight's 'Acute Ischemic Stroke Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of acute ischemic stroke in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Advanced Wound Care Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
As per DelveInsight, the global Advanced Wound Care Market was valued at USD 10.44 billion in 2023, growing at a CAGR of 10.82% during the forecast period from 2024 to 2030, to reach USD 19.29 billion by 2030. The demand for advanced wound care is predominantly associated with the rising incidence of chronic wounds associated with various chronic disorders such as diabetes, and cancer, and also with the rising incidence of active wounds comprising burns, and surgical wounds, among others
Alcohol Use Disorder Market
https://www.delveinsight.com/report-store/alcohol-use-disorder-market
DelveInsight's "Alcohol Use Disorder (AUD) Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AUD, historical and forecasted epidemiology, as well as the AUD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Neurodon, Sangamo Therapeutics, NKGen Biotech, Asceneuron, TrueBinding, Alector, Cognition Therapeutics, Anavex Life Scie here
News-ID: 3651467 • Views: …
More Releases from DelveIinsight Business Research
Hidradenitis Suppurativa Market Expected to Experience Major Growth by 2034, Acc …
DelveInsight's "Hidradenitis Suppurativa Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hidradenitis Suppurativa, historical and forecasted epidemiology as well as the Hidradenitis Suppurativa market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Hidradenitis Suppurativa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hidradenitis Suppurativa Market Forecast
https://www.delveinsight.com/sample-request/hidradenitis-suppurativa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Hunter Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
The Hunter Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hunter Syndrome pipeline products will significantly revolutionize the Hunter Syndrome market dynamics.
DelveInsight's "Hunter Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hunter Syndrome, historical and forecasted epidemiology as well as the Hunter Syndrome market trends in the United…
Hyperlipidemia Market to Show Remarkable Growth Trends from 2023 to 2032, DelveI …
The Hyperlipidemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hyperlipidemia pipeline products will significantly revolutionize the Hyperlipidemia market dynamics.
DelveInsight's "Hyperlipidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hyperlipidemia, historical and forecasted epidemiology as well as the Hyperlipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Leigh Syndrome Market Growth to Accelerate in Forecast Period (2024-2034), Delve …
The Leigh Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Leigh Syndrome pipeline products will significantly revolutionize the Leigh Syndrome market dynamics.
DelveInsight's "Leigh Syndrome Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Leigh Syndrome, historical and forecasted epidemiology as well as the Leigh Syndrome market trends in the United…
More Releases for Alzheimer
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Alzheimer Diagnostic Tests Market
GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
